These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 1098359

  • 1. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
    Callaghan N, Fitzpatrick E, O'Mahony JB.
    Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
    [Abstract] [Full Text] [Related]

  • 2. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
    Feigenson JS, Sweet RD, McDowell FH.
    Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003 May; 103(11):21-4. PubMed ID: 14681961
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
    Truelle JL, Chanelet J, Bastard J, Six P, Emile J.
    Nouv Presse Med; 1977 Oct 08; 6(33):2987-90. PubMed ID: 22844
    [Abstract] [Full Text] [Related]

  • 10. Piribedil therapy in Parkinson's disease. Use of the drug in the retard form.
    Mentenopoulos G, Katsarou Z, Bostantjopoulou S, Logothetis J.
    Clin Neuropharmacol; 1989 Feb 08; 12(1):23-8. PubMed ID: 2713865
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses.
    Fahn S, Isgreen WP.
    Neurology; 1975 Aug 08; 25(8):695-700. PubMed ID: 807869
    [Abstract] [Full Text] [Related]

  • 13. Caffeine and the antiparkinsonian response to levodopa or piribedil.
    Shoulson I, Chase T.
    Neurology; 1975 Aug 08; 25(8):722-4. PubMed ID: 125389
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M, Castro-Caldas A, Del Signore S, Rascol O.
    Mov Disord; 2003 Apr 08; 18(4):418-25. PubMed ID: 12671949
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr 08; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 18. Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa.
    Zeldowicz LR, Hubermann J.
    Can Med Assoc J; 1973 Oct 06; 109(7):588-93. PubMed ID: 4582563
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.